Orchestra BioMed Holdings Inc.
OBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OBIO
Orchestra BioMed Holdings Inc. is a clinical-stage biomedical company developing two flagship product candidates: AVIM Therapy for hypertension and Virtue SAB for in-stent restenosis, with a focus on advancing pivotal clinical trials.
Key risk: Clinical and regulatory uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Orchestra BioMed Holdings Inc..
Orchestra BioMed Holdings Inc. is a clinical-stage biomedical company developing two flagship product candidates: AVIM Therapy for hypertension and Virtue SAB for in-stent restenosis, with a focus on advancing pivotal clinical trials.
- As of June 30, 2026, Orchestra BioMed held $110.0 million in cash, cash equivalents, and marketable securities, including $20.5 million in cash and cash equivalents and $89.5 million in marketable securities [sec_mda · as of 2026-08-10].
- The company reported a net loss of $23.8 million for the quarter ended June 30, 2026, with total revenue of $0.1 million [latest reported financials (as of 2026-06-30)].
- Accumulated deficit was $383.3 million as of March 31, 2026 [sec_mda · as of 2026-05-12].
- Orchestra BioMed is prioritizing spending on its two flagship programs: the BACKBEAT Trial for AVIM Therapy and the Virtue Trial for Virtue SAB [sec_mda · as of 2026-08-10].
- The company received $20.0 million from Medtronic and $15.0 million from Ligand in May 2026 to support clinical development [sec_mda · as of 2026-05-12].
What works
- Orchestra BioMed has a substantial cash position of $110.0 million as of June 30, 2026, providing runway to advance its clinical programs [sec_mda · as of 2026-08-10].
- The company has secured strategic financing from Medtronic and Ligand, indicating external validation and support for its pipeline [sec_mda · as of 2026-05-12].
- Management expects current cash and commitments to fund operations into the fourth quarter of 2027, suggesting a clear near-term financial plan [sec_mda · as of 2025-11-10].
What to weigh
- Orchestra BioMed has incurred significant operating losses and negative cash flows since inception, with an accumulated deficit of $383.3 million as of March 31, 2026 [sec_mda · as of 2026-05-12].
- The company has no approved products and relies on future regulatory approvals and commercialization success, which are uncertain [sec · filed 2025-10-28].
- Operating expenses are expected to increase as the company scales clinical trials, potentially requiring additional financing [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Cash and marketable securities position as of June 30, 2026
“We had $110.0 million in cash and cash equivalents and marketable securities at June 30, 2026, comprised of $20.5 million in cash and cash equivalents and $89.5 million in marketable securities.”
SEC MD&A · August 10, 2026
Net loss for the three months ended March 31, 2026
“Our net losses were $20.7 million and $18.8 million for the three months ended March 31, 2026 and 2025, respectively.”
SEC MD&A · May 12, 2026
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, we had an accumulated deficit of $383.3 million.”
SEC MD&A · May 12, 2026
Funding from Medtronic and Ligand in May 2026
“On May 1, 2026, we received $20.0 million pursuant to the Medtronic Loan Agreement and an additional $15.0 million from Ligand pursuant to the Royalty Purchase Agreement.”
SEC MD&A · May 12, 2026
Risks & what to watch (4)›
Key risks
- Clinical and regulatory uncertainty — Product candidates require regulatory approval; failure to achieve milestones could harm prospects [sec · filed 2025-10-28].
- History of operating losses — Significant accumulated deficit of $383.3M as of March 31, 2026, with no guarantee of future profitability [sec_mda · as of 2026-05-12].
- Dependence on additional financing — Increasing clinical costs may require future capital raises, which could dilute shareholders [sec_mda · as of 2026-08-10].
- Competitive product landscape — Competing products and product candidates may impact market adoption and revenue [sec · filed 2025-10-28].
What to watch
- Progress and enrollment updates for the BACKBEAT Trial for AVIM Therapy [sec_mda · as of 2026-08-10].
- Initiation and enrollment of the Virtue Trial for Virtue SAB [sec_mda · as of 2026-08-10].
- Any regulatory milestones or FDA interactions for the company's product candidates [sec · filed 2025-10-28].
- Cash burn rate and any additional financing or partnership announcements [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 16, 2026 · How we verify sources →
Run Orchestra BioMed Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Orchestra BioMed Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
16.4 months
OCF -$19M · Net income -$24M
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
7 buys · 4 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$125.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 10,075,812 | $42.8M |
| rtw investments, lp | 8,306,063 | $35.3M |
| vanguard capital management llc | 4,408,638 | $18.7M |
| alyeska investment group, l.p. | 1,000,000 | $4.3M |
| millennium management llc | 702,543 | $3.0M |
| blackrock, inc. | 635,714 | $2.7M |
| geode capital management, llc | 485,492 | $2.1M |
| affinity asset advisors, llc | 402,550 | $1.7M |
| charles schwab investment management inc | 265,499 | $1.1M |
| knott david m jr | 253,651 | $1.1M |
Showing top 10 of 64 institutional holders of Orchestra BioMed Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 2.6%
- Days to cover
- 6.3
- Shares short
- 972,590
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Orchestra BioMed Holdings Inc.?
Orchestra BioMed Holdings Inc. is a clinical-stage biomedical company developing two flagship product candidates: AVIM Therapy for hypertension and Virtue SAB for in-stent restenosis, with a focus on advancing pivotal clinical trials.
What is Orchestra BioMed Holdings Inc.'s lead drug candidate?
Orchestra BioMed Holdings Inc.'s most advanced tracked candidate is avim therapy (Phase 3) for Hypertension in patients indicated for a cardiac pacemaker.
Who is the CEO of Orchestra BioMed Holdings Inc.?
Mr. David P. Hochman is the chief executive officer of Orchestra BioMed Holdings Inc. (OBIO).
Where is Orchestra BioMed Holdings Inc. headquartered?
Orchestra BioMed Holdings Inc. (OBIO) is headquartered in New Hope, PA, United States.
What therapeutic areas does Orchestra BioMed Holdings Inc. focus on?
Orchestra BioMed Holdings Inc. develops therapies across Oncology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.